1. Home
  2. SELF vs RNTX Comparison

SELF vs RNTX Comparison

Compare SELF & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SELF

Global Self Storage Inc.

N/A

Current Price

$5.52

Market Cap

58.1M

Sector

Real Estate

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

N/A

Current Price

$0.82

Market Cap

65.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SELF
RNTX
Founded
1983
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.1M
65.3M
IPO Year
1997
2017

Fundamental Metrics

Financial Performance
Metric
SELF
RNTX
Price
$5.52
$0.82
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$6.00
$10.00
AVG Volume (30 Days)
29.1K
486.3K
Earning Date
05-08-2026
05-15-2026
Dividend Yield
5.25%
N/A
EPS Growth
N/A
44.16
EPS
0.11
N/A
Revenue
$12,705,245.00
N/A
Revenue This Year
$3.04
N/A
Revenue Next Year
$3.47
N/A
P/E Ratio
$50.45
N/A
Revenue Growth
1.40
N/A
52 Week Low
$4.73
$0.69
52 Week High
$5.63
$2.18

Technical Indicators

Market Signals
Indicator
SELF
RNTX
Relative Strength Index (RSI) 60.00 48.41
Support Level $4.99 $0.69
Resistance Level $5.63 $1.05
Average True Range (ATR) 0.16 0.07
MACD 0.04 0.01
Stochastic Oscillator 71.69 63.28

Price Performance

Historical Comparison
SELF
RNTX

About SELF Global Self Storage Inc.

Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: